Les Tari
Hoofd Techniek/Wetenschap/O&O bij CIDARA THERAPEUTICS, INC.
Vermogen: 241 423 $ op 30-04-2024
Actieve functies van Les Tari
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CIDARA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-03-2019 | - |
Corporate Officer/Principal | 01-07-2014 | 01-03-2019 |
Loopbaan van Les Tari
Eerdere bekende functies van Les Tari
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01-03-2007 | 01-03-2014 |
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Oprichter | 01-01-2003 | 01-01-2007 |
Corporate Officer/Principal | 01-01-2003 | 01-01-2007 | |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Corporate Officer/Principal | 01-01-2001 | 01-01-2003 |
Opleiding van Les Tari
University of Manitoba | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Canada | 2 |
Operationeel
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Distribution Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CIDARA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Distribution Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |